Loading stock data…
Sunshine Biopharma (SBFM)
$1.15+0.01 (+1.32%)
Market ClosedLast close Sep 8
Sunshine Biopharma, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sunshine Biopharma, Inc. in the Healthcare sector is trading at $1.15 with a market capitalization of $5M. Wall Street consensus targets $56.00 (1 analysts), implying a +4769.6% move over the next 12 months. The stock is currently near its 52-week low of $1.01, remaining 85.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +4769.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.09M↓ | $8.58M↓ | $9.42M | $9.41M↑ | $8.90M |
| Gross Profit | $2.18M↓ | $3.03M↓ | $3.07M↓ | $3.42M↑ | $2.73M |
| Operating Income | -$1.40M↑ | -$1.66M↓ | -$531,963↑ | -$992,846↑ | -$1.30M |
| Net Income | -$1.24M↑ | -$2.14M↓ | -$883,820↑ | -$1.77M↓ | -$1.18M |
Peer Comparison
JNJUNHPFE
Fundamentals
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is develo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.67M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.07%
Volume
Today's trading volume
287,806
Recent News
EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer
Sunshine Biopharma Inc. (NASDAQ:SBFM) on Wednesday released an update regarding its proprietary oncology initiative, outlining key next steps for its K1.1 mRNA lipid nanoparticle program. K1.1 mRNA Preclinical Results The K1.1 mRNA gene acts as a tumor suppressor frequently mutated in hepatocellular carcinoma, non-small cell lung cancer, and pancreatic cancer. These genetic mutations form “cold” tumors that evade host immune responses, leading to poor prognosis in patients. Preclinical studies c
EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug
Sunshine Biopharma Inc. (NASDAQ:SBFM) announced on Wednesday that it has secured regulatory approval to introduce its generic Enalapril tablets across the Canadian market, signaling a significant strategic step into first-line antihypertensive treatments. The newly approved medication, the generic equivalent of the well-known brand Vasotec, will be available to patients in multiple dosage strengths: 2.5mg, 5mg, 10mg, and 20mg tablets. Sunshine Biopharma currently markets 60 generic prescription
EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval
Pharmaceutical firm Sunshine Biopharma Inc. (NASDAQ:SBFM) on Tuesday said it received regulatory approval to introduce its 2mg generic Dienogest tablets to the Canadian market. The significant milestone marks the company’s strategic expansion into women’s healthcare, specifically targeting first-line therapy for pelvic pain associated with endometriosis. Read Also: Sunshine Biopharma Stock Rallies On Canadian Approval For Generic Amoxicillin The generic prescription drugs maker in June implement
Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested
These are the upcoming stock splits for the week of June 1 to June 5, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate move that increases the number of shares outstanding while reducing the price of each share proportionally. Nothing changes about the company’s overall value, but the lower share price can make the stock appear more accessible to everyday investors and, in some cases, help boost trading activity. Not all stock splits work that way, however. Many companies t